Synergistic associations of metformin and <scp>GLP</scp> ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes
In patients with T2D, dual metformin and GLP-1 RA treatment was associated with a 39% lower incidence of adiposity-related cancers and a 67% lower mortality, with a striking impact on cancer-related outcomes.
Authors
- David R. J. Riley (ORCID: https://orcid.org/0000-0002-0905-6524)
- Uazman Alam (ORCID: https://orcid.org/0000-0002-3190-1122)
- Theresa Hydes (ORCID: https://orcid.org/0000-0002-7768-6886)
- Alex E. Henney (ORCID: https://orcid.org/0000-0002-8066-9470)
- Daniel James Cuthbertson (ORCID: https://orcid.org/0000-0002-6128-0822)
- Matthew Anson (ORCID: https://orcid.org/0000-0001-9991-7369)
- Megan Heague (ORCID: https://orcid.org/0009-0005-1419-1324)
Institutions
- University of Liverpool (GB)
- University of Staffordshire (GB)
- Aintree University Hospitals NHS Foundation Trust (GB)
- Liverpool Womens NHS Foundation Trust (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1111/dom.70267
- Citations
- 1
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81